Texas Instruments Trading Volume Plummets 64.12% Despite Ranking Third in Consecutive Gains

On June 30, 2025, Texas Instruments Incorporated (TXN) experienced a significant decline in trading volume, with a 64.12% decrease from the previous day, resulting in a total trading volume of 6.38 billion. Despite this drop, TXN managed to close the day with a slight increase of 0.26%, marking its third consecutive day of gains and a cumulative increase of 1.09% over the past three days.

On June 4, 2025, Senator Bill Hagerty introduced the National Innovation Act, which was passed by the Senate on June 2025 with a 68-30 vote. This bipartisan-supported legislation aims to enhance national innovation by fostering a more competitive and dynamic economy. The Act is expected to have a positive impact on Texas Instruments Incorporated (TXN) by promoting technological advancements and innovation, which are crucial for the company's growth and competitiveness in the semiconductor industry.

On June 30, 2025, the FDA announced the Commissioner's National Priority Voucher (CNPV) program, designed to expedite the review of new drug and biologic applications. This program is expected to significantly reduce review times to 1-2 months, compared to the current PDUFA goal timelines of 6-12 months. The CNPV program will prioritize companies aligned with U.S. national priorities, such as addressing health crises, delivering innovative cures, and increasing domestic drug manufacturing. Texas Instruments Incorporated (TXN) may benefit from this program if it engages in partnerships or collaborations with pharmaceutical companies that qualify for the CNPV, potentially leading to faster approvals and market entry for innovative medical technologies.